Galmed Pharma (GLMD) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Join SI Premium – FREE
Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35).
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
